Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial.

التفاصيل البيبلوغرافية
العنوان:	Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial.
المؤلفون:	Fencer, Maria G., Davis, Catherine H., Jieqi Liu, Galan, Mark A., Spencer, Kristen R.
المصدر:	Journal of Investigative Medicine High Impact Case Reports; Jan-Dec2022, Vol. 10, p1-6, 6p
مستخلص:	Sarcomatoid hepatocellular carcinoma (SHCC) is a rare variant of liver cancer that lacks treatment options. The IMbrave trail demonstrated the efficacy of atezolizumab and bevacizumab (A + B) in patients with unresectable hepatocellular carcinoma but excluded patients with sarcomatoid variants. Herein, we describe a case of disease control achieved using the IMbrave regimen in a patient with sarcomatoid hepatocellular carcinoma. [ABSTRACT FROM AUTHOR]
	Copyright of Journal of Investigative Medicine High Impact Case Reports is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات:	Complementary Index

الوصف
تدمد:	23247096
DOI:	10.1177/23247096221129470